BridgeMD
New treatment option for ER+ Breast Cancer
Official title 4FMFES-PET Imaging of ER+ Advanced Breast Cancers
ClinicalTrials.gov ID: NCT04824014
What this study is testing
- What it's testing
- Estrogen Receptor (ER) is a crucial prognostic factor and treatment target in breast cancer patients. Knowledge of its status greatly influences the choice of the optimal course of treatment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Advanced breast cancer patients, i.e. stage 3 or 4 diseases.
- Aged 18 or older at the time of breast cancer diagnosis.
- Histopathologic review confirming diagnosis of ER positive breast cancer.
- Male patients, although rare, can participate.
- Patient must have given informed consent.
You likely can't join if
- Patients who are pregnant or nursing.
- Patients unable to tolerate PET/CT for 30 minutes.
- Patients taking anti-ER hormone therapy that can pharmacologically blockade estrogen receptors (ex: Tamoxifen, Fulvestrant). Patients can undergo...
See the full eligibility criteria
- Advanced breast cancer patients, i.e. stage 3 or 4 diseases.
- Aged 18 or older at the time of breast cancer diagnosis.
- Histopathologic review confirming diagnosis of ER positive breast cancer.
- Male patients, although rare, can participate.
- Patient must have given informed consent.
- ECOG performance status 0-3.
- ER must be positive in at least 10% of tumor cells in either the core biopsy or a therapeutic surgical resection.
- Any HER2-neu status.
- Patient eligible for and willing to receive systemic treatment.
- Patients who are pregnant or nursing.
- Patients unable to tolerate PET/CT for 30 minutes.
- Patients taking anti-ER hormone therapy that can pharmacologically blockade estrogen receptors (ex: Tamoxifen, Fulvestrant). Patients can undergo 4FMFES-PET if anti-ER therapy was interrupted at least 8 weeks prior...
The study team makes the final eligibility decision.
Where it's taking place
- Sherbrooke, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sherbrooke, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.